LKKTETQ raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-22 and is reviewed periodically as new material appears.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
=== Neurosurgical research and innovations === Maroon has conducted extensive research into neurotrauma, brain tumors, and diseases of the spine, which led to many innovative techniques for diagnosing and treating these disorders. Maroon was the first to publish on the use of ultrasound to detect venous air emboli (1968). Maroon et al. were the first to publish on the use of ultrasound to detect air in patients during neurosurgical procedures (1969) and to assess ophthalmic artery reversal of flow, indicating a thrombosis of the carotid artery (1969). Maroon et al. published the simplified instrumentation for performing microvascular surgery in 1973, and in 1975, they pioneered the microsurgical approach to intra-orbital tumors. In 1977, they pioneered the use of CT scanning as a guidance system for performing intracranial biopsy. In the same year, Maroon published the first paper on "burning hands" syndrome related to sports-related spinal cord injuries in JAMA. In 1982, Maroon et al. pioneered the radical orbital decompression procedure for severe dysthyroid exophthalmos. In 1985, they were the first to compare microsurgical disc removal with chemonucleolysis and in 1986, they were the first to use a carbon dioxide laser in the management of lymphangiomas of the orbit. That year, Maroon et al. were among the first to describe their surgery outcomes with microlumbar discectomy. In 1987, Maroon and Onik introduced percutaneous automated discectomy as a new minimally invasive way to remove lumbar discs and subsequently published extensively on this technique.
In December 2000, Dutch journalist Marjon van Royen found that "because the chemical is sprayed in Colombia from planes on inhabited areas, there have been consistent health complaints [in humans]. Burning eyes, dizziness and respiratory problems being most frequently reported." In some areas, 80 percent of the children of the indigenous community fell sick with skin rashes, fever, diarrhoea and eye infections. Because the glyphosate is sprayed from the air, there is a much higher chance of human error when spraying suspected illegal coca plantations. In many cases the wrong fields are sprayed, resulting in not only a total loss of the farmer's crop- but the loss of that field altogether as nothing will grow where the herbicide has been sprayed. Though official documentation of the health effects of glyphosate spraying in Colombia are virtually non-existent, neighbouring Ecuador has conducted studies to determine the cause of mysterious illnesses amongst people living along the border of Colombia and has since demanded that no aerial sprayings occur within 10 km of the border because of the damages caused to the people, animals and environment in that area. In 2015, Colombia announced a ban on using glyphosate in these programs due to concerns about human toxicity of the chemical.
== Properties == The physical and chemical properties of magnetic nanoparticles largely depend on the synthesis method and chemical structure. In most cases, the particles range from 1 to 100 nm in size and may display superparamagnetism.
=== Economics === In the US, generic methadone tablets are inexpensive, with retail prices ranging from $0.25 to $2.50 per defined daily dose. Methadone maintenance clinics in the US may be covered by private insurance, Medicaid, or Medicare. Medicare covers methadone under the prescription drug benefit, Medicare Part D, when it is prescribed for pain, but not when it is used for opioid dependence treatment because it cannot be dispensed in a retail pharmacy for this purpose. In California methadone maintenance treatment is covered under the medical benefit. Patients' eligibility for methadone maintenance treatment is most often contingent on them being enrolled in substance abuse counseling. People on methadone maintenance in the US either have to pay cash or if covered by insurance must complete a pre-determined number of hours per month in therapeutic groups or counseling. The United States Department of Veteran's Affairs (VA) Alcohol and Drug Dependence Rehabilitation Program offers methadone services to eligible veterans enrolled in the VA health care system. Methadone maintenance treatment (MMT) cost analyses often compare the cost of clinic visits versus the overall societal costs of illicit opioid use. A preliminary cost analysis conducted in 2016 by the US Department of Defense determined that methadone treatment, which includes psychosocial and support services, may cost an average of $126.00 per week or $6,552.00 per year.
Italy: On 3 May 2015, Italian astronaut Samantha Cristoforetti became the first person to drink freshly brewed coffee in space. Commercial firms Lavazza and Argotec developed an espresso machine, called ISSpresso, for the International Space Station. It can also brew other hot drinks, such as tea, hot chocolate, and broth. While the device serves as a quality-of-life improvement aboard the station, it is also an experiment in fluid dynamics in space. The brewing machine and drinking cups were specially designed to work with fluids in low gravity. Japan: The Japan Aerospace Exploration Agency (JAXA) have developed traditional Japanese foods and drinks such as matcha, yōkan, ramen, sushi, soups, and rice with ume for consumption in orbit. The foods have been produced in collaboration with Japanese food companies such as Ajinomoto, Meiji Dairies, and Nissin Foods. Korea: In April 2008, South Korea's first astronaut, Yi So-yeon, was a crew member on the International Space Station and brought a modified version of Korea's national dish, kimchi. It took three research institutes several years and over one million dollars in funding to create a version of the fermented cabbage dish that was suitable for space travel. Russia: On the International Space Station, the Russian crew has a selection of over 300 dishes.
Sources: en.wikipedia.org
==== Huntington's Disease ==== Mutant huntingtin protein disrupts AMPAR-mediated synaptic transmission by impairing receptor trafficking, leading to synaptic dysfunction and neuronal loss in Huntington's disease models.
== Etymology == The term "botany" comes from the Ancient Greek word botanē (βοτάνη) meaning "pasture", "herbs" "grass", or "fodder"; Botanē is in turn derived from boskein (Greek: βόσκειν), "to feed" or "to graze". Traditionally, botany has also included the study of fungi and algae by mycologists and phycologists respectively, with the study of these three groups of organisms remaining within the sphere of interest of the International Botanical Congress.
== Side effects == Oral use of cortisone has a number of potential systemic adverse effects, including asthma, hyperglycemia, insulin resistance, diabetes mellitus, osteoporosis, anxiety, depression, amenorrhoea, cataracts, glaucoma, Cushing's syndrome, increased risk of infections, and impaired growth. With topical application, it can lead to thinning of the skin, impaired wound healing, increased skin pigmentation, tendon rupture, and skin infections (including abscesses).
Consensus scoring Selecting candidates by voting of multiple scoring functions May lose the relationship between protein-ligand structural information and scoring criterion Cluster analysis Represent and cluster candidates according to protein-ligand 3D information Needs meaningful representation of protein-ligand interactions.
Sources: en.wikipedia.org
Greater than 10%: difficulty sleeping, anxiety, nervousness, abdominal pain/cramps, nausea and/or vomiting, low energy, joint/muscle pain, and headache. Less than 10%: loss of appetite, diarrhea, constipation, thirstiness, increased energy, feeling down, irritability, dizziness, skin rash, delayed ejaculation, erectile dysfunction, and chills. A variety of other adverse events have also been reported with less than 1% incidence.
=== Digestibility-corrected AAS, DIAAS === DIAAS considers the profile of the essential amino acids that are actually absorbed. This value is calculated by estimating the amount of each EAA absorbed in the "test protein" by comparing how much of each EAA went into the mouth and how much was pumped out of the end of the small intestines. This was then turned into a profile Ai by dividing the amounts in milligrams of each EAA with the grams of the test protein eaten. From then on, the calculation is similar:
=== List of superintendents === Shawn Joseph (interim 2025–2026; 2026-present) Millard House II (2023–2025) Monica Goldson, CEO (interim 2018–2019; 2019–2023) Kevin M. Maxwell, CEO (2013–2018) Alvin Crawley (interim 2012–2013) William R. Hite, Jr. (interim 2008–2009; 2009–2012) John E. Deasy (2006–2008) Howard A. Burnett (interim 2005–2006) André J. Hornsby (2003–2005) Iris T. Metts (1999–2003) Jerome Clark (1995–1999) Edward M. Felegy (1991–1995) John A. Murphy (1984–1991) Edward J. Feeney (1976–1984) Carl W. Hassel (1970–1976) William S. Schmidt (1951–1970) G. Gardner Shugart (1944–1951) Nicholas Orem Sr. (1921–1943) E.S. Burroughs (1915–1921) Frederick Sasscer Jr. (1902–1914)
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.